Skip to main content
. 2021 Nov 25;74:103712. doi: 10.1016/j.ebiom.2021.103712

Figure 6.

Figure 6

4G10-ADC impairs SARS-CoV-2 variants infectivity. (a) Western blot analysis of PNGase F or Endo H treated S protein immunoblotted by purified antibodies, mice sera, or COVID-19 convalescent sera. Black circle, g-spike; arrowhead, ng-spike. (b) Binding affinity of g-spike or ng-spike with immobilized anti-spike mAb#1 measured by BioLayer Interferometry. (c-h) Luciferase activity was measured at 48 h to determine antibody neutralizing activity or viral infectivity in HEK293T-ACE2 cells; n=3 for all experiments. Statistically significant by one-way ANOVA, Tukey post hoc tests. **p < 0.01, ***p < 0.001 (n = 3 with mean ± SD shown). (c,e,g) Heat maps of the relative neutralizing activity of indicated concentration of antibodies from purified mAb#1 (c), mice sera (e), COVID-19 convalescent sera (g) against indicated SARS-CoV-2 (black), Alpha variant (blue), and Beta variant (red) pseudovirus. (d,f,h) Assessment of SARS-CoV-2, Alpha, and Beta variants infectivity in HEK293T-ACE2 cells after administering 40ng/mL 4G10-ADC with 1ng/mL anti-spike mAb#1 (d) 200 folds diluted mouse serum#4 (f) or 3200 folds diluted COVID-19 convalescent serum#3 (h). (i) Proposed mechanism of 4G10-ADC action on SARS-CoV-2 infected cells.